OBJECTIVE: To determine the long-term impact of immunologic discordance (viral load <50 copies/mL and CD4+ count <=200 cells/mm3) in antiretroviral-naive patients initiating combination antiretroviral therapy (cART). METHODS: Our analysis included antiretroviral-naive individuals from a population-based Canadian Observational Cohort that initiated cART after January 1, 2000, and achieved virologic suppression. Multivariable Cox proportional hazards regression was used to examine the association between 1-year and 2-year immunologic discordance and time to death from all-causes. Correlates of immunologic discordance were assessed with logistic regression. RESULTS: Immunologic discordance was observed in 19.9% (404 of 2028) and 10.2% (176 of 1721) of individuals at 1 and 2 years after cART initiation, respectively. Two-year immunologic discordance was associated with an increased risk of death [adjusted hazard ratio = 2.69; 95% confidence interval (CI): 1.26 to 5.78]. One-year immunologic discordance was not associated with death (adjusted hazard ratio = 1.12; 95% CI: 0.54 to 2.30). Two-year immunologic discordance was associated with older age (aOR per decade = 1.23; 95% CI: 1.03 to 1.48), male gender (aOR = 1.86; 95% CI: 1.09 to 3.16), injection drug use (aOR = 2.75; 95% CI: 1.81 to 4.17), and lower baseline CD4+ count (aOR per 100 cells = 0.24; 95% CI: 0.19 to 0.31) and viral load (aOR per log10 copies/mL = 0.46; 95% CI: 0.33 to 0.65). CONCLUSIONS: Immunologic discordance after 2 years of cART in antiretroviral-naive individuals was significantly associated with an increased risk of mortality.
OBJECTIVE: To determine the long-term impact of immunologic discordance (viral load <50 copies/mL and CD4+ count <=200 cells/mm3) in antiretroviral-naive patients initiating combination antiretroviral therapy (cART). METHODS: Our analysis included antiretroviral-naive individuals from a population-based Canadian Observational Cohort that initiated cART after January 1, 2000, and achieved virologic suppression. Multivariable Cox proportional hazards regression was used to examine the association between 1-year and 2-year immunologic discordance and time to death from all-causes. Correlates of immunologic discordance were assessed with logistic regression. RESULTS: Immunologic discordance was observed in 19.9% (404 of 2028) and 10.2% (176 of 1721) of individuals at 1 and 2 years after cART initiation, respectively. Two-year immunologic discordance was associated with an increased risk of death [adjusted hazard ratio = 2.69; 95% confidence interval (CI): 1.26 to 5.78]. One-year immunologic discordance was not associated with death (adjusted hazard ratio = 1.12; 95% CI: 0.54 to 2.30). Two-year immunologic discordance was associated with older age (aOR per decade = 1.23; 95% CI: 1.03 to 1.48), male gender (aOR = 1.86; 95% CI: 1.09 to 3.16), injection drug use (aOR = 2.75; 95% CI: 1.81 to 4.17), and lower baseline CD4+ count (aOR per 100 cells = 0.24; 95% CI: 0.19 to 0.31) and viral load (aOR per log10 copies/mL = 0.46; 95% CI: 0.33 to 0.65). CONCLUSIONS: Immunologic discordance after 2 years of cART in antiretroviral-naive individuals was significantly associated with an increased risk of mortality.
Authors: Steven J Reynolds; Joseph B Sempa; Agnes N Kiragga; Kevin Newell; Gertrude Nakigozi; Ronald Galiwango; Ron Gray; Thomas C Quinn; David Serwadda; Larry Chang Journal: AIDS Patient Care STDS Date: 2014-10-07 Impact factor: 5.078
Authors: Frederik N Engsig; Robert Zangerle; Olga Katsarou; Francois Dabis; Peter Reiss; John Gill; Kholoud Porter; Caroline Sabin; Andrew Riordan; Gerd Fätkenheuer; Félix Gutiérrez; Francois Raffi; Ole Kirk; Murielle Mary-Krause; Christoph Stephan; Patricia Garcia de Olalla; Jodie Guest; Hasina Samji; Antonella Castagna; Antonella d'Arminio Monforte; Adriane Skaletz-Rorowski; Jose Ramos; Giuseppe Lapadula; Cristina Mussini; Lluís Force; Laurence Meyer; Fiona Lampe; Faroudy Boufassa; Heiner C Bucher; Stéphane De Wit; Greer A Burkholder; Ramon Teira; Amy C Justice; Tim R Sterling; Heidi M Crane; Jan Gerstoft; Jesper Grarup; Margaret May; Geneviève Chêne; Suzanne M Ingle; Jonathan Sterne; Niels Obel Journal: Clin Infect Dis Date: 2014-01-22 Impact factor: 9.079
Authors: Charles F Gilks; A Sarah Walker; Paula Munderi; Cissy Kityo; Andrew Reid; Elly Katabira; Ruth L Goodall; Heiner Grosskurth; Peter Mugyenyi; James Hakim; Diana M Gibb Journal: PLoS One Date: 2013-02-21 Impact factor: 3.240
Authors: Reuben Granich; Somya Gupta; Amitabh B Suthar; Caoimhe Smyth; David Hoos; Marco Vitoria; Mariangela Simao; Catherine Hankins; Bernard Schwartlander; Renee Ridzon; Brigitte Bazin; Brian Williams; Ying-Ru Lo; Craig McClure; Julio Montaner; Gottfried Hirnschall Journal: Curr HIV Res Date: 2011-09 Impact factor: 1.581
Authors: Jim Young; Mina Psichogiou; Laurence Meyer; Sylvie Ayayi; Sophie Grabar; Francois Raffi; Peter Reiss; Brian Gazzard; Mike Sharland; Félix Gutierrez; Niels Obel; Ole Kirk; José M Miro; Hansjakob Furrer; Antonella Castagna; Stéphane De Wit; Josefa Muñoz; Jesper Kjaer; Jesper Grarup; Geneviève Chêne; Heiner Bucher Journal: PLoS Med Date: 2012-03-20 Impact factor: 11.069
Authors: Giuseppe Lapadula; Liliane Chatenoud; Andrea Gori; Francesco Castelli; Simona Di Giambenedetto; Massimiliano Fabbiani; Franco Maggiolo; Emanuele Focà; Nicoletta Ladisa; Laura Sighinolfi; Massimo Di Pietro; Angelo Pan; Carlo Torti Journal: PLoS One Date: 2015-05-28 Impact factor: 3.240